[Evaluation of the myocardial protection of trimetazidine during percutaneous coronary intervention: a multi-center randomized and controlled clinical study].
OBJECTIVE
To evaluate the myocardial protection effects of trimetazidine during percutaneous coronary intervention (PCI).


METHODS
101 patients from 5 hospitals with stable or unstable angina pectoris were enrolled in this study. All the patients were randomized into two groups: a trimetazidine group (n=54) and a control group (n=47). The trimetazidine group received oral trimetazidine 20 mg three times a day for (5±2) days before coronary angiography and a loading dose of 60 mg 30 minutes before PCI. The daily routine dosage was continued for 4 weeks after the procedure. The control group received similar treatment except trimetazidine. For each patient, the angina pectoris attacks, CK-MB, electrocardiogram and echocardiogram were noted.


RESULTS
Angina did not occur in trimetazidine group during the procedure but occurred in 12 patients (25.5%) in the control group (P<0.001). The changes of ST-segment and T wave during balloon dilatation in PCI procedure were less in the trimetazidine group (60.8% vs 78.3%, P<0.05). Ejection fraction in the trimetazidine group was higher than that in the control group 4 weeks [(66.6±7.1)% vs (63.0±7.7)%, P=0.03] after PCI.


CONCLUSIONS
Trimetazidine could reduce the frequency of angina pectoris attacks and myocardial damage during PCI. It also improves left ventricular function during follow-up after PCI.
Chen
Yun-dai
YD
Department of Cardiology, Chinese PLA General Hospital, Beijing 100853, China. cyundai@medmail.com.cn
Zhao
Li-kun
LK
Tian
Feng
F
Du
Zhi-min
ZM
Jiang
Hong
H
Wei
Meng
M
D000368:Aged; D000787:Angina Pectoris / Q000628:therapy*; D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D014292:Trimetazidine / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000627:therapeutic use*
D014665:Vasodilator Agents; D014292:Trimetazidine